The startup develops a dopamine-transporter imaging agent for the early detection and treatment of dopamine-related brain disorders, including Parkinson's Syndrome and dementia. This platform enables healthcare professionals to achieve accurate diagnoses and implement timely interventions for patients suffering from these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing dopamine-related brain disorders, such as Parkinson's Syndrome and dementia, often relies on subjective clinical assessments and can be delayed due to limited access to specialized imaging technologies. This can lead to delayed treatment and poorer patient outcomes.
Solution
LikeMinds has developed a dopamine-transporter imaging agent designed to improve the accuracy and accessibility of diagnosing dopamine-related brain disorders. This imaging agent allows healthcare professionals to visualize dopamine transporter levels in the brain, providing quantitative data to aid in the early detection and differentiation of conditions like Parkinson's disease and certain types of dementia. By enabling earlier and more accurate diagnoses, the technology facilitates timely intervention and personalized treatment strategies. The company's focus is on providing affordable and accessible diagnostic tools for improved patient care in neurology and related fields.
Target Audience
The primary target audience includes healthcare professionals, such as neurologists, radiologists, and geriatricians, involved in the diagnosis and management of patients with movement disorders and cognitive decline.
Features
- Dopamine-transporter imaging agent for visualizing dopamine transporter levels in the brain.
- Provides quantitative data to aid in the diagnosis of Parkinson's disease, dementia, and other dopamine-related disorders.
- Aims to improve diagnostic accuracy compared to relying solely on clinical assessments.